Combination antiretroviral therapy

Expert Opinion on Pharmacotherapy

Volumn 12, Issue 7, 2011, Pages 995-998

  Domingo, Pere ^a   Vidal, Francesc ^b  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

Author keywords

Antiretroviral therapy; eradication; HIV 1 infection; toxicity

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; LAMIVUDINE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIVIRAL THERAPY; CD4 LYMPHOCYTE COUNT; COMBINATION ANTIRETROVIRAL THERAPY; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; REVIEW; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; HIV INFECTIONS; HIV-1; HUMANS; TREATMENT OUTCOME;

EID: 79953856801     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.2011.567001     Document Type: Review

References (41)

1. Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med 1996;334:1011-17 (Pubitemid 26124452)
2. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS Clinical Trials Group 320 Study Team. N Engl J Med 1997;337:725-33 (Pubitemid 27417971)
3. DHHS/Henry J. Kaiser Family Foundation Panel on Clinical Practices for the Treatment of HIV infection. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. October 2008 revision. Available from: http://aidsinfo.nih.gov/ContentFiles/AboutHIVTreatment Guidelines-FS-en.pdf [Accessed 25 January 2011]
4. Staszewski S, Morales-Ramirez J, Tashima KT, et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999;341:1865-73
5. Lennox JL, Dejesus E, Berger DS, et al. Raltegravir versus Efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010;55:39-48
6. Cooper DA, Heera J, Goodrich J, et al. Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 2010;201:803-13
7. Simmons P. When paradigms fall: the demise of "hit hard, hit early". Res Initiat Treat Action 1999;5:11-12
8. Wein LM, D'Amato RM, Perelson AS. Mathematical analysis of antiretroviral therapy aimed at HIV-1 eradication or maintenance of low viral loads. J Theor Biol 1998;192:81-98 (Pubitemid 28254408)
9. Rosenberg DH, Arling PA. Landmark article Aug 12, 1944: penicillin in the treatment of meningitis. By D.H. Rosenberg and P.A. Arling. JAMA 1984;251:1870-6
10. d'Arminio Monforte A, Lepri AC, Rezza G, et al. Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral näve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Näve Patients. AIDS 2000;14:499-507 (Pubitemid 30209692)
11. Boffito M, Miralles D, Hill A. Pharmacokinetics, efficacy, and safety of darunavir/ritonavir 800/100 mg once-daily in treatment-näve and-experienced patients. HIV Clin Trials 2008;9:418-27
12. Arnaiz JA, Mallolas J, Podzamczer D, et al. Continued indinavir versus switching to indinavir/ritonavir in HIV-infected patients with suppressed viral load. AIDS 2003;17:831-40 (Pubitemid 36547655)
13. Hicks CB, Cahn P, Cooper DA, et al. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug reSistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006;368:466-75 (Pubitemid 44142769)
14. Joly V, Jidar K, Tatay M, Yeni P. Enfuvirtide: from basic investigations to current clinical use. Expert Opin Pharmacother 2010;11:2701-13
15. Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials. AIDS 2009;23:2289-300
16. Towner WJ, Cassetti I, Domingo P, et al. Etravirine: clinical review of a treatment option for HIV type-1-infected patients with non-nucleoside reverse transcriptase inhibitor resistance. Antivir Ther 2010;15(6):803-16
17. Mocroft A, Phillips AN, Soriano V, et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. AIDS Res Hum Retroviruses 2005;21:527-36 (Pubitemid 40944314)
18. Villarroya F, Domingo P, Giralt M. Lipodystrophy associated with highly active anti-retroviral therapy for HIV infection: the adipocyte as a target of anti-retroviral-induced mitochondrial toxicity. Trends Pharmacol Sci 2005;26:88-93 (Pubitemid 40170171)
19. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009;361:2230-40
20. Yeni P, Hammer SM, Hirsch MS, et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA 2004;292:251-65 (Pubitemid 38918003)
21. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. January 10, 2011; 1-166. Available from: http://www.aidsinfo.nih. gov/ContentFiles/AdultandAdolescentGL. pdf. [Accessed 20 January 2011]
22. Panel de Expertos de Gesida; Plan Nacional sobre el Sida. [AIDS Study Group/Spanish AIDS Plan consensus document on antiretroviral therapy in adults with human immunodeficiency virus infection (updated January 2010)]. Enferm Infecc Microbiol Clin 2010;28:362.e1-91
23. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007;44:441-6 (Pubitemid 46147630)
24. Gras L, Kesselring AM, Griffin JT, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr 2007;45:183-92 (Pubitemid 46869811)
25. Pursuing Later Treatment Options II (PLATO II) Project Team for the Collaboration of Observational HIV Epidemiological Research Europe (COHERE), Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years. Arch Intern Med 2010;170:410-19
26. Antiretroviral Therapy Cohort Collaboration. Causes of death in HIV-1-infected patients treated with antiretroviral therapy 1996-2006: collaborative analysis of 13 HIV cohort studies. Clin Infect Dis 2010; 50:1387-96
27. Reekie J, Kosa C, Engsig F, et al. Relationship between current level of immunodeficiency and non-acquired immunodeficiency syndrome-defining malignancies. Cancer 2010;116:5306-15
28. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. JAMA 2003;289:2978-82 (Pubitemid 37430100)
29. Grunfeld C, Delaney JA, Wanke C, et al. Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM study. AIDS 2009;23:1841-9
30. Choi AI, Shlipak MG, Hunt PW, et al. HIV-infected persons continue to lose kidney function despite successful antiretroviral therapy. AIDS 2009;23:2143-9
31. Mallon PW. HIV and bone mineral density. Curr Opin Infect Dis 2010;23:1-8
32. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS defining cancers among human immunodeficiency virus-infected individuals. Cancer 2005;104:1505-11 (Pubitemid 41356166)
33. Kirk GD, Merlo C, O'Driscoll P, et al. HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis 2007;45:103-10 (Pubitemid 46984625)
34. Bini EJ, Park J, Francois F. Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med 2006;166:1626-31 (Pubitemid 44232372)
35. Giralt M, Domingo P, Guallar JP, et al. HIV-1 infection alters gene expression in adipose tissue, which contributes to HIV-1/HAART-associated lipodystrophy. Antivir Ther 2006;11:729-40 (Pubitemid 44497168)
36. McArthur JC, Steiner J, Sacktor N, Nath A. Human immunodeficiency virus-associated neurocognitive disorders: mind the gap. Ann Neurol 2010;67:699-714
37. Effros RB, Fletcher CV, Gebo K, et al. Aging and infectious diseases: workshop on HIV infection and aging: what is known and future research directions. Clin Infect Dis 2008;47:542-53
38. UNAIDS-A year in review. Available from: http://www.unaids.org/en/ resources/presscentre/featurestories/2010/december/20101223fsyearend/. [Accessed 20 January 2011]
39. Montaner JS, Lima VD, Barrios R, et al. Association of highly active antiretroviral therapy coverage, population viral load, and yearly new HIV diagnoses in British Columbia, Canada: a population-based study. Lancet 2010;376:532-9
40. Charlebois E, Porco T, Das-Douglas M, Havlir D. The Effect of Expanded Antiretroviral Treatment (ART) Strategies on the MSM HIV Epidemic in San Francisco. 17th Conference on Retroviruses and Opportunistic Infections; 16-19 February 2010; San Francisco. Paper # 996
41. Moreno S, Lopez Aldeguer J, Arribas JR, et al. The future of antiretroviral therapy: challenges and needs. J Antimicrob Chemother 2010;65:827-35